II. Materials And Methods
This study of Extra-nodal Gastrointestinal (GI) Lymphoma was conducted in the Institute of Child Health, Egmore, Madras Medical College, Department of Pathology, Chennai during the period between July 2008 and June 2014. All the GI lymphoma cases reported in resected specimens with age group between 1to 14years were included for the study. Detailed history of the cases regarding age, sex, history, type of procedure, details of gross characteristics were obtained for all the 30 resected GI Lymphoma cases were recorded in the Paediatric Surgical pathology records.Hematoxylin and Eosin (H&E) stained, 4 microns thick sections of the paraffin tissue blocks of resected specimens were reviewed.
Method Of Data Collection
The clinico-pathological parameterssuch age (1-14years), gender, tumour size (<5 and >5cm), tumour location (Ileum, Caecum, ascending colon, liver and Spleen), macroscopic appearance were evaluated. Age more than 14years, non-neoplastic lesions and benign tumors of GIT, lymphoma of mediastinaladenopathy, peripheral adenopathy, testicular and para-pharyngeal mass were excluded from the study.Lymphomas were classified based on St. Jude Staging. Microscopic appearances were divided into B cell and T cell type.
All the cases of GI Lymphoma diagnosed by H&E stained section were subjected to immunohistochemistry for a panel of 4 markers -CD3,CD20,CD45 and Ki-67. The immunohistochemicallystained slides were analyzed for the presence of reaction, cellular localization, percentage of cells stained and intensity of reaction. Nuclear staining was assessed for Ki -67. Cytoplasmic staining was assessed for T-cell, B-cell and both T & B-cell for CD3, CD20 and CD45 respectively.
The Ki-67 labeling index (LI) was determined by counting at high power view 1000 tumour cell nuclei in areas of the section. The Ki-67 labeling index for the 30 tumours ranged from 0 % to 98% with a mean labeling index of 58.4%. Labeling index greater than 60% indicates High Ki-67. Labeling index lesser than 60% indicates Low Ki -67.
Statistical analysis:
Data was analysedusing SSPS version 11.5 which consisted of computing the frequency counts and percentages for qualitative variables and mean for the quantitative variables. Numerical data were expressed as mean with standard deviation. Categorical variable were expressed as frequency and percentage.Survival analysis was calculated using Kaplan-Meier test and presented as cumulative survival rates. Comparison between two survival curves was done using Breslow test. A probability (P-value) less than 0.05 was considered statistically significant.
III. Observation And Results
In the study period of 60 months from July 2008 to June 2014, a total of 6300 specimens were received in the Institute of Child health, Egmore, Department of Pathology, Madras Medical College for histological examination. Total number of GI resected specimens received was 2834. The total numbers of nonneoplastic, benign and malignant cases were 2784,12 and 38 respectively. Thus the distribution of nonneoplastic lesions was 98.2 %, of benign tumors were 0.42% and of malignant tumors were 1.34% among the GI specimens. Of these, GI Lymphoma was reported in 30cases.
Pediatric GI Lymphoma had a peak incidence in the age group of 5 -9years. Twenty-one (70%) cases of gastrointestinal lymphoma were reported in males and nine (30%) in females. The clinical features associated with paediatric GI lymphomawere Abdominal pain (76.7%), Abdominal swelling (70%), Vomiting (40%), Obstruction/Intussusception (20%) and Constipation (16.7%). Among the study samples, 15 cases (50%) had tumor less than 5 cm in size and another 15 cases (50%) were 5cm or more in size.
Topographic distribution:
The most common location of GILymphoma was at the Ileum which constituted about 66.7% (n = 20 cases) of the cases. Two 
Histopathological findings :
The distribution of various Histological subtypes in GI Lymphoma in our sample size were grouped into Burkitt's [ Figure4 Among the 3 patients with recurrence of disease after treatment, only one is alive and is now on second line chemotherapy. There were 5 deaths in our study with 2 death due to disease recurrence, 2 due to chemotherapy complication and 1 due to sepsis.
IV. Survival Analysis
The mean duration of follow-up was 26 months (range of 7 months to 67 months). The Overall and disease free survival rates in our study were 83.3% and 89.2% respectively (FIG 6 & 7) . While calculating disease free survival those with progressive disease are non responders were not included. The correlation between the overall survival and various clinicopathological parameters had shown that no bone marrow infiltration (p <0.001), localised disease (p < 0.001), early stage disease (p < 0.001), non Burkitt type (p = 0.031), response to chemotherapy (p <0.001) and low Ki67 labelling index had statistically significantly influenced the overall survival. When the disease free survival was correlated with the same clinicopathological parameters, no bone marrow infiltration (p <0.001), localized disease (p <0.001), early stage (p 0.006) and response to chemotherapy (p <0.001) were found to have significant effect on disease free survival as shown in Table 3 .
The 
V. Discussion
Malignant lymphomas are the third most common cancer in the childhood. The distinction between non-Hodgkin's lymphoma of adults and those of children is important because children usually present with diffuse extra-nodal disease when compared with adults, in whom the primary nodal disease is more common [6] .Primary Gastrointestinal [GI] malignancies are the commonest extra-nodal site of involvement in children. Nevertheless, primary GI lymphomas are rare in children and represent less than 5% of all pediatric population with very limited data available in Indian population. [7] Many biological markers have been examined as potential tools for the evaluation of the biological behavior of gastrointestinal lymphoma in order to predict its clinical outcome. Among these, immunohistochemical staining of proliferation marker Ki-67 has been proposed to be of prognostic value. In the present study, immuno-histochemical evaluation was done in 30 cases of gastrointestinal Lymphoma and an attempt was made to correlate the Ki-67 labeling index with the known prognostic factors of GI Lymphoma
The peak age incidence of GI lymphoma has been reported in 5 to 15 years age group in the literature [6, 7] . In the present study, mean age of pediatric GI lymphoma was 6.10 years (Standard deviation ± 2.482). In the study done byMorsi et al, [8] the incidence of GI Lymphoma in male and female was 75.7% and 24.3% respectively. In concurrence with the above study, a significant male predominance (76%) of GI Lymphoma was noted with female patients being accounted for 24% of cases.
The most common site of pediatric GI Lymphoma in present study is the small bowel (85%), followed by ileo-caecal region (20%), large intestine (6.7%) and spleen (6.7%). This is almost similar to the most of the reported series in the literature. [8, 9, 10] Abdominal pain was the most common presentation (76.7%) in the present studyfollowed by abdominal swelling (70%), vomiting (40%), intestinal obstruction (20%) and constipation (16.7%). In contrast to most of other studies, none of our patients presented with generalized lymphadenopathy. Bone marrow aspiration was done in all cases, which revealed bone marrow infiltration in only 5 cases (16.7%). The incidence of bone marrow infiltration was slightly higher in the present study when compared to other studies, which range from 3.5 to 9.1%. [10] All the patients in the study group underwent complete surgical removal of the diseased segment of bowel or organ. The ideal treatment approach in GI Lymphoma remains controversial. Radical tumor resection followed by chemotherapy in early disease, and limited or no resection followed by poly-chemotherapy in advanced disease may be the justified approach. However recent studies done by Rainaet al 2006, have proposed the use of chemotherapy alone as an effective treatment option in primary GI lymphoma in all stages. [11] The Role Of Ki- The examination of resected specimen in the study group revealed Burkitt lymphoma (33%), MALToma, DLBCL, Anaplastic lymphoma, Lymphoblastic lymphoma and Hodgkins. The incidence of various pathological subtypes in our study was comparable to the study by Morsi et al.
Ranjanbandyopadhyay et al has showed that there was 50% distal small bowel involvement shown in [ Table 4 ] except one case all were males and presented with intestinal obstruction in half of cases. All cases had intestinal growth with 50% shows regional involvement. This is consistent with the current study with male predominance, small bowel involvement with regional lymph node.
With cut-off value of 60%, we found that Ki 67 has statistically significant impact on overall survival in patients with pediatric GI lymphoma. However, high Ki-67 value, which was associated with poorer overall survival in the study, has not shown any significance in predicting disease free survival.
Cell proliferation rate is a vital parameter in grading neoplasm and predicting clinical outcome. In our study, Burkitt lymphoma showed highest Ki 67 positivity ranging between 80 -98%, followed by lymphoblastic lymphoma (92%), anaplastic lymphoma (80%), DLBCL (40-80%) and MALToma (10-50%). The present study clearly demonstrates that Ki-67 may add both diagnostic and prognostic value in pediatric GI lymphoma.
Ann Arbor classification or its modification by Musshoff was applied by most author to describe the extent of disease. In our study we applied St. Jude satging system to describe the extent of disease. Most of our patients belonged to stage II disease with disease free survival of 88% when compared to advanced (stage IV E) disease with disease free survival of 37.5%. In a similar study by Patte C et al, 2001 , showed that patients with Stage II has disease free survival of about 98 to 100% versus 76% in those with most extensive disease. Most other publications have stated an survival rate ranging from 24 to 87% for intestinal lymphoma, which was 83.3% in our series and 80.6 % in other prospective study by Ahmed et al. In view of diverging definitions, various staging classification, small cohort of patients and different histological definition in most publication, it is difficult to have a more detailed analysis concerning stage and histological subtypes.
The survival analysis in the present study ( figure 6 & 7) has shown that bone marrow infiltration, extensive disease, Burkitt's type, advanced stage of disease, non responders to chemotherapy and high Ki 67 values were significantly associated with poorer overall survival. This fact matches with other studies showing that the outcome depends more on the tumor burden at diagnosis [12] and can be predicted by high Ki 67 value, Serum LDH, interleukin-2, B-2 microglobulin levels. [10] Bone marrow infiltration, extensive disease, Burkitt's type, advanced stage of disease and nonresponders to chemotherapy were in addition found to significantly influence the disease free survival. This is consistent with earlier reports, [13, 14] demonstrating that disease free survival is influenced by the extent of disease at the initiation of therapy.
Raina V et al in the study sample of 77 new cases of primary gastrointestinal lymphoma over the period of 15 years have found that gastrointestinal tract is the most common extranodal site and the treatment modality in his studies demonstrates that chemotherapy alone has emerged as an effective option despite surgical resection and conclude organ preservation strategy using chemotherapy alone which can be successfully employed in a significant number of patients with primary Non Hodgkins Lymphoma.
Assigning patients to appropriate therapy depending upon their risk stratification has become the rule with different protocols. A patient with localised disease requires less intensive therapy than those with extensive disease. It is therefore necessary that patient should not be over-treated. Pediatric GI lymphoma patients in whom complete resection has been done require only few course of chemotherapy without compromising final outcome. On the contrary, patients with high risk groups (those with advanced or extensive disease) required intensive therapy with multiple drugs to achieve similar outcome in the present study.
To conclude, we noticed a higher prevalence of Burkitt's among primary paediatric GI Lymphomas and prognosis can be interpreted by using Ki 67 proliferative index. Hence, Ki-67 labelling index could be helpful for clinicians to recognise patients with high risk for recurrence and poor survival in combination with other prognostic factors like bone marrow infiltration, histological type, stage and response to chemotherapy.
VI. Conclusion
The incidence of paediatric GI lymphoma was lower (0.48%) in the present study when compared to western population (1.2%).The mean age of presentation was 6.1 year with male predominance.Different types of lymphoma are associated with significantly different Ki-67 values. In this study, a 60% Ki 67 cut-off value appear to have a predict value for overall survival and can help thus clinicians to distinguish between GI lymphoma with good and poor outcome.Stage is the most significant prognostic factor and localised disease is associated with better survival. In conclusion the role of Ki-67 in growth and aggressiveness of GI lymphoma is complex and poorly understood. Ki-67 labelling index could be helpful for clinicians to recognise patients with high risk for recurrence and poor survival in combination with other prognostic factors like bone marrow infiltration, histological type, stage and response to chemotherapy. 
